Most linked-to pages

Showing below up to 50 results in range #1 to #50.

1. Not specified‏‎ (80 links)
2. 3‏‎ (54 links)
3. 2‏‎ (40 links)
4. 4‏‎ (40 links)
5. 1‏‎ (20 links)
6. Property:Has Toxicity Level‏‎ (13 links)
7. Property:Has Usefulness Rating‏‎ (13 links)
8. Property:Has treatment name‏‎ (12 links)
9. Not rated‏‎ (9 links)
10. 2.5‏‎ (6 links)
11. Property:Has Toxicity Explanation‏‎ (6 links)
12. Integrative Oncologist‏‎ (6 links)
13. Property:Has OS with‏‎ (5 links)
14. Property:Has OS without‏‎ (5 links)
15. Property:Has PFS with‏‎ (5 links)
16. Property:Has PFS without‏‎ (5 links)
17. Alternative Treatment Centers and Clinics‏‎ (5 links)
18. CBD‏‎ (4 links)
19. CBD (Cannabidiol)‏‎ (4 links)
20. Cannabigerol (CBG)‏‎ (4 links)
21. Cannabis‏‎ (4 links)
22. Cannabis and Cannabis-derived Products (e.g., Sativex)‏‎ (4 links)
23. Ellagic Acid‏‎ (4 links)
24. Fish Oil (Omega-3 Fatty Acids: EPA and DHA)‏‎ (4 links)
25. Fish oil‏‎ (4 links)
26. Gamma-Linolenic Acid (GLA)‏‎ (4 links)
27. Garlic (Allium sativum)‏‎ (4 links)
28. Not applicable‏‎ (4 links)
29. PSK (Polysaccharide Krestin) and other polysaccharides‏‎ (4 links)
30. Perillyl Alcohol/Limonene‏‎ (4 links)
31. Sodium R Lipoate and Hydroxycitrate (METABLOC)‏‎ (4 links)
32. " in your query was not closed by a matching "‏‎ (4 links)
33. 23 months median survival, with 47% at 2 years‏‎ (3 links)
34. 5‏‎ (3 links)
35. 6.1 months for all patients, 5.9 months for EGFR amplified patients‏‎ (3 links)
36. AVAglio trial: 16.8 months; RTOG trial: 15.7 months‏‎ (3 links)
37. BCNU (Carmustine) and Gliadel (Carmustine Wafers)‏‎ (3 links)
38. Bevacizumab (Avastin)‏‎ (3 links)
39. CBG‏‎ (3 links)
40. CCNU (Lomustine)‏‎ (3 links)
41. Chloroquine‏‎ (3 links)
42. Chloroquine and Hydroxychloroquine‏‎ (3 links)
43. Comparable to standard TMZ treatments, but timing affects management of side effects.‏‎ (3 links)
44. Curcumin‏‎ (3 links)
45. Ellagic acid‏‎ (3 links)
46. GLA‏‎ (3 links)
47. Garlic‏‎ (3 links)
48. Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months‏‎ (3 links)
49. ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response.‏‎ (3 links)
50. Keppra‏‎ (3 links)